(Q37786089)

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Mechanisms of disease: The epidemiology of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Epidemiological trend in the distribution of cancer in Kashmir Valley

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

7 January 2021

Cancer statistics, 2007

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Medicare payments from diagnosis to death for elderly cancer patients by stage at diagnosis.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The origins of bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The association between smoking, beverage consumption, diet and bladder cancer: a systematic literature review

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Alterations of the p53 gene in occupational bladder cancer in workers exposed to aromatic amines

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Urothelial tumorigenesis: a tale of divergent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Molecular subtypes of bladder cancer: Jekyll and Hyde or chalk and cheese?

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Factors affecting recurrence and progression in superficial bladder tumours.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Frequent FGFR3 mutations in papillary non-invasive bladder (pTa) tumors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Frequent activating mutations of FGFR3 in human bladder and cervix carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Loss of heterozygosity at 4p16.3 and mutation of FGFR3 in transitional cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The incidence of thanatophoric dysplasia mutations in FGFR3 gene is higher in low-grade or superficial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

A novel form of FGF receptor-3 using an alternative exon in the immunoglobulin domain III

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Receptor specificity of the fibroblast growth factor family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Differential splicing in the extracellular region of fibroblast growth factor receptor 1 generates receptor variants with different ligand-binding specificities

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The health economics of bladder cancer: a comprehensive review of the published literature.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

A gene encoding a fibroblast growth factor receptor isolated from the Huntington disease gene region of human chromosome 4.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Genomic organization of the human fibroblast growth factor receptor 3 (FGFR3) gene and comparative sequence analysis with the mouse Fgfr3 gene.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Isolation of an additional member of the fibroblast growth factor receptor family, FGFR-3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Human fibroblast growth factor receptor 3 gene (FGFR3): genomic sequence and primer set information for gene analysis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Structural and Functional Diversity in the FGf Receptor Multigene Family

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Spatio-temporal expression of FGFR 1, 2 and 3 genes during human embryo-fetal ossification.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

FGFR activation in skeletal disorders: too much of a good thing

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

FGF signaling pathways in endochondral and intramembranous bone development and human genetic disease

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Distinct missense mutations of the FGFR3 lys650 codon modulate receptor kinase activation and the severity of the skeletal dysplasia phenotype

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Graded activation of fibroblast growth factor receptor 3 by mutations causing achondroplasia and thanatophoric dysplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Frequent translocation t(4;14)(p16.3;q32.3) in multiple myeloma is associated with increased expression and activating mutations of fibroblast growth factor receptor 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

FGFR3 and Ras gene mutations are mutually exclusive genetic events in urothelial cell carcinoma.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Novel fibroblast growth factor receptor 3 (FGFR3) mutations in bladder cancer previously identified in non-lethal skeletal disorders

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Whole genome oligonucleotide-based array comparative genomic hybridization analysis identified fibroblast growth factor 1 as a prognostic marker for advanced-stage serous ovarian adenocarcinomas

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Specificity of receptor tyrosine kinase signaling: transient versus sustained extracellular signal-regulated kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

FGFR3 and Tp53 Mutations in T1G3 Transitional Bladder Carcinomas: Independent Distribution and Lack of Association with Prognosis

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Role of activating fibroblast growth factor receptor 3 mutations in the development of bladder tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Mutations in the transmembrane domain of FGFR3 cause the most common genetic form of dwarfism, achondroplasia

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

PIK3CA mutations are an early genetic alteration associated with FGFR3 mutations in superficial papillary bladder tumors.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Prospective study of FGFR3 mutations as a prognostic factor in nonmuscle invasive urothelial bladder carcinomas.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Inverted papilloma as a cause of high-grade ureteral obstruction

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Urothelial transitional cell carcinoma with endophytic growth patterns: a discussion of patterns of invasion and problems associated with assessment of invasion in 18 cases

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Low frequency of molecular changes and tumor recurrence in inverted papillomas of the urinary tract.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

FGFR3 protein expression and its relationship to mutation status and prognostic variables in bladder cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Molecular characterization of early-stage bladder carcinomas by expression profiles, FGFR3 mutation status, and loss of 9q.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Fibroblast growth factor receptor 3 induces gene expression primarily through Ras-independent signal transduction pathways.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The economic consequences of prostate and bladder cancer in the UK.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Identification of fibroblast growth factor receptor 3 mutations in urine sediment DNA samples complements cytology in bladder tumor detection

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Detection of bladder cancer recurrence by microsatellite analysis of urine

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Cellular signaling by fibroblast growth factor receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Identification of tyrosine residues in constitutively activated fibroblast growth factor receptor 3 involved in mitogenesis, Stat activation, and phosphatidylinositol 3-kinase activation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Profound ligand-independent kinase activation of fibroblast growth factor receptor 3 by the activation loop mutation responsible for a lethal skeletal dysplasia, thanatophoric dysplasia type II

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

A lipid-anchored Grb2-binding protein that links FGF-receptor activation to the Ras/MAPK signaling pathway

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The phosphotyrosine phosphatase SHP2 is a critical mediator of transformation induced by the oncogenic fibroblast growth factor receptor 3

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Requirement of Shp-2 tyrosine phosphatase in lymphoid and hematopoietic cell development

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The docking protein FRS2alpha controls a MAP kinase-mediated negative feedback mechanism for signaling by FGF receptors

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Sustained ERK1/2 but not STAT1 or 3 activation is required for thanatophoric dysplasia phenotypes in PC12 cells.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Differential PTEN protein expression profiles in superficial versus invasive bladder cancers.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

FGF receptors ubiquitylation: dependence on tyrosine kinase activity and role in downregulation

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The thanatophoric dysplasia type II mutation hampers complete maturation of fibroblast growth factor receptor 3 (FGFR3), which activates signal transducer and activator of transcription 1 (STAT1) from the endoplasmic reticulum

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

The kinase activity of fibroblast growth factor receptor 3 with activation loop mutations affects receptor trafficking and signaling

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

K644E/M FGFR3 mutants activate Erk1/2 from the endoplasmic reticulum through FRS2 alpha and PLC gamma-independent pathways

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Enhanced signaling and morphological transformation by a membrane-localized derivative of the fibroblast growth factor receptor 3 kinase domain

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Oncogenic properties of the mutated forms of fibroblast growth factor receptor 3b.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Knockdown by shRNA identifies S249C mutant FGFR3 as a potential therapeutic target in bladder cancer.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Cancer. Addiction to oncogenes--the Achilles heal of cancer

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014

Targeting the extracellular domain of fibroblast growth factor receptor 3 with human single-chain Fv antibodies inhibits bladder carcinoma cell line proliferation.

7 January 2021

1 reference

https://api.crossref.org/works/10.1016%2FJ.UROLONC.2010.07.014